Cargando…

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial

BACKGROUND: Glioblastoma multiforme (GBM) is a rare and deadly disease, with a reported average incidence rate of 3.19 cases per 100,000 inhabitants. Fotemustine, a third-generation nitrosourea with an alanine phosphor carrier that facilitates cellular penetration, has been extensively investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinelli, Alfredo, Lamberti, Giuseppe, Cerbone, Luigi, Cordua, Nadia, Buonerba, Carlo, Peluso, Gianfranco, Di Lorenzo, Giuseppe, De Placido, Sabino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076126/ https://www.ncbi.nlm.nih.gov/pubmed/29979390 http://dx.doi.org/10.1097/MD.0000000000011254

Ejemplares similares

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study
por: Addeo, Raffaele, et al.
Publicado: (2019)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study
por: Guida, Michele, et al.
Publicado: (2010)

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation
por: Ristić-Fira, Aleksandra M, et al.
Publicado: (2009)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide
por: Topkan, Erkan, et al.
Publicado: (2022)

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009)

Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
por: Toren, Amos, et al.
Publicado: (2016)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
por: Faustino, Alexandre Ciuffi, et al.
Publicado: (2020)

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide
por: Topkan, Erkan, et al.
Publicado: (2020)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
por: Gebhardt, Brian J, et al.
Publicado: (2014)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
por: Lee, Chooi Yeng, et al.
Publicado: (2016)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
por: Heynckes, Sabrina, et al.
Publicado: (2019)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

HGG-04. ZINC ENHANCES TEMOZOLOMIDE CYTOTOXICITY IN PEDIATRIC GLIOBLASTOMA MULTIFORME MODEL SYSTEM
por: Toren, Amos, et al.
Publicado: (2020)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
por: Brandes, Alba A., et al.
Publicado: (2009)

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
por: Yung, W K A, et al.
Publicado: (2000)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment
por: Jakubowicz-Gil, Joanna, et al.
Publicado: (2013)

Elimination of Cancer Stem-Like Cells and Potentiation of Temozolomide Sensitivity by Honokiol in Glioblastoma Multiforme Cells
por: Lai, I-Chun, et al.
Publicado: (2015)

In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme
por: Borhani, Samira, et al.
Publicado: (2017)

Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Publicado: (2020)

Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells
por: Cheng, Shu-Yu, et al.
Publicado: (2021)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide
por: Feng, Shao-Wei, et al.
Publicado: (2023)

Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry
por: Braun, Klaus, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_vu7q8bvhf3lt5gm2fs71hal34f